Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
1.600
-0.020 (-1.23%)
At close: Sep 17, 2025, 4:00 PM EDT
1.600
0.00 (0.00%)
After-hours: Sep 17, 2025, 4:10 PM EDT

Company Description

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe.

It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.

In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories.

The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product.

Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Mainz Biomed N.V.
Mainz Biomed logo
CountryGermany
Founded2021
IPO DateNov 5, 2021
IndustryDiagnostics & Research
SectorHealthcare
Employees26
CEOGuido Baechler

Contact Details

Address:
Robert Koch Strasse 50
Mainz, 55129
Germany
Phone49 6131 554 2860
Websitemainzbiomed.com

Stock Details

Ticker SymbolMYNZ
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$5.00
CIK Code0001874252
CUSIP NumberN5436L101
ISIN NumberNL0015000LC2
SIC Code2834

Key Executives

NamePosition
Guido BaechlerChief Executive Officer and Executive Director
Dr. Christopher Von Toerne P.M.P., Ph.D.Chief Operating Officer
Dr. Frank Krieg-SchneiderChief Technology Officer
Dr. Moritz Eidens Ph.D.Chief Science Officer and Executive Director
Stefan ErlachHead of Human Resources
Philipp FreeseChief Business Officer

Latest SEC Filings

DateTypeTitle
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 5, 20256-KReport of foreign issuer
Aug 5, 2025424B3Prospectus
Aug 4, 2025EFFECTNotice of Effectiveness
Jul 30, 2025F-1Registration statement for certain foreign private issuers
Jul 18, 2025UPLOADFiling
Jul 15, 2025DRS[Cover] Draft Registration Statement
Jun 5, 20256-KReport of foreign issuer
May 21, 2025424B3Prospectus
May 21, 20256-KReport of foreign issuer